🇺🇸 Arotinolol Hydrochloride in United States

105 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 105

Most-reported reactions

1. Malaise — 14 reports (13.33%)
2. Pyrexia — 13 reports (12.38%)
3. Fall — 12 reports (11.43%)
4. Pneumonia — 11 reports (10.48%)
5. Decreased Appetite — 10 reports (9.52%)
6. Diabetes Mellitus — 10 reports (9.52%)
7. Alanine Aminotransferase Increased — 9 reports (8.57%)
8. Aspartate Aminotransferase Increased — 9 reports (8.57%)
9. Hepatic Function Abnormal — 9 reports (8.57%)
10. Anaemia — 8 reports (7.62%)

Source database →

Frequently asked questions

Is Arotinolol Hydrochloride approved in United States?

Arotinolol Hydrochloride does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Arotinolol Hydrochloride in United States?

Sumitomo Pharma (Suzhou) Co., Ltd. is the originator. The local marketing authorisation holder may differ — check the official source linked above.